Macrophages in osteoarthritis: pathophysiology and therapeutics.

Osteoarthritis (OA) is the most common cause of disability in worldwide population, which is characterized by cartilage breakdown, synovial fibrosis, osteophyte formation and pain. Synovial inflammation is usually found in both early and late stages in most of the OA patients. Macrophages, the major component of the mononuclear phagocyte system, play a critical role in OA pathogenesis through the induction of inflammatory mediators, growth factors and proteinases. So, drugs that can target macrophages and macrophage-associated inflammatory pathways at an appropriate stage may help to inhibit or slow down the progression of OA. However, despite an emerging role of synovial macrophages in OA pathogenesis, little is known about the biology of synovial tissue macrophages, and attempts to target macrophages therapeutically have had limited success. But the use of selective targets of macrophages may minimize the side effects and support the promising therapeutic strategy in the treatment of OA. More pre-clinical animal models and clinical trials are necessary to evaluate the role of selective targets of macrophages in the prevention and treatment of OA. This review article discusses the association of macrophages in OA development and possible OA therapeutics by targeting macrophages.